412 related articles for article (PubMed ID: 33559714)
1. Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis.
Hamar A; Szekanecz Z; Pusztai A; Czókolyová M; Végh E; Pethő Z; Bodnár N; Gulyás K; Horváth Á; Soós B; Bodoki L; Bhattoa HP; Nagy G; Tajti G; Panyi G; Szekanecz É; Domján A; Hodosi K; Szántó S; Szűcs G; Szamosi S
Osteoporos Int; 2021 Aug; 32(8):1621-1629. PubMed ID: 33559714
[TBL] [Abstract][Full Text] [Related]
2. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.
Gulyás K; Horváth Á; Végh E; Pusztai A; Szentpétery Á; Pethö Z; Váncsa A; Bodnár N; Csomor P; Hamar A; Bodoki L; Bhattoa HP; Juhász B; Nagy Z; Hodosi K; Karosi T; FitzGerald O; Szücs G; Szekanecz Z; Szamosi S; Szántó S
Clin Rheumatol; 2020 Jan; 39(1):167-175. PubMed ID: 31522318
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
[TBL] [Abstract][Full Text] [Related]
4. Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients.
Juhász B; Gulyás K; Horváth Á; Végh E; Pusztai A; Szentpétery Á; Pethő Z; Bodnár N; Hamar A; Bodoki L; Bhattoa HP; Szekanecz É; Hodosi K; Domján A; Szamosi S; Horváth C; Szántó S; Szűcs G; Raterman HG; Lems WF; FitzGerald O; Szekanecz Z
BMC Musculoskelet Disord; 2021 Sep; 22(1):817. PubMed ID: 34556105
[TBL] [Abstract][Full Text] [Related]
5. Comparison of peripheral quantitative computed tomography forearm bone density versus DXA in rheumatoid arthritis patients and controls.
Juhász B; Gulyás K; Horváth Á; Pethő Z; Bhattoa HP; Váncsa A; Szekanecz É; Horváth C; Kocsis J; Horváth Z; Hodosi K; Szántó S; Szűcs G; Szekanecz Z
Osteoporos Int; 2017 Apr; 28(4):1271-1277. PubMed ID: 27942777
[TBL] [Abstract][Full Text] [Related]
6. The Janus kinase inhibitor tofacitinib inhibits TNF-α-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes.
Kawaguchi Y; Waguri-Nagaya Y; Tatematsu N; Oguri Y; Kobayashi M; Nozaki M; Asai K; Aoyama M; Otsuka T
Clin Exp Rheumatol; 2018; 36(4):559-567. PubMed ID: 29352846
[TBL] [Abstract][Full Text] [Related]
7. Effects of tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: A metabolomic approach.
Soós B; Hamar A; Pusztai A; Czókolyová M; Végh E; Szamosi S; Pethő Z; Gulyás K; Kerekes G; Szántó S; Szűcs G; Christians U; Klawitter J; Seres T; Szekanecz Z
Front Med (Lausanne); 2022; 9():1011734. PubMed ID: 36438060
[TBL] [Abstract][Full Text] [Related]
8. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
[No Abstract] [Full Text] [Related]
10. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
12. Associations of vascular and bone status in arthritis patients.
Pusztai A; Hamar A; Czókolyová M; Gulyás K; Horváth Á; Végh E; Pethő Z; Szamosi S; Balogh E; Bodnár N; Bodoki L; Szentpétery Á; Bhattoa HP; Kerekes G; Juhász B; Szekanecz É; Hodosi K; Domján A; Szántó S; Raterman HG; Lems WF; Szekanecz Z; Szűcs G
Sci Rep; 2021 Sep; 11(1):19504. PubMed ID: 34593938
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
14. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
15. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.
Schulze-Koops H; Strand V; Nduaka C; DeMasi R; Wallenstein G; Kwok K; Wang L
Rheumatology (Oxford); 2017 Jan; 56(1):46-57. PubMed ID: 28028154
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib: A Review in Rheumatoid Arthritis.
Dhillon S
Drugs; 2017 Dec; 77(18):1987-2001. PubMed ID: 29139090
[TBL] [Abstract][Full Text] [Related]
17. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Hodge JA; Kawabata TT; Krishnaswami S; Clark JD; Telliez JB; Dowty ME; Menon S; Lamba M; Zwillich S
Clin Exp Rheumatol; 2016; 34(2):318-28. PubMed ID: 26966791
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
[TBL] [Abstract][Full Text] [Related]
19. Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis.
Czókolyová M; Hamar A; Pusztai A; Tajti G; Végh E; Pethő Z; Bodnár N; Horváth Á; Soós B; Szamosi S; Szentpéteri A; Seres I; Harangi M; Paragh G; Kerekes G; Bodoki L; Domján A; Hodosi K; Seres T; Panyi G; Szekanecz Z; Szűcs G
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291691
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis.
van Vollenhoven R; Lee EB; Strengholt S; Mojcik C; Valdez H; Krishnaswami S; Biswas P; Lazariciu I; Hazra A; Clark JD; Hodge J; Wang L; Choy E
Arthritis Rheumatol; 2019 May; 71(5):685-695. PubMed ID: 30427585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
